Galecto Stock Forecast, Price & News

-0.07 (-1.61 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume33,080 shs
Average Volume283,348 shs
Market Capitalization$108.37 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GLTO News and Ratings via Email

Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter.

Galecto logo

About Galecto

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.33 out of 5 stars

Medical Sector

241st out of 2,220 stocks

Pharmaceutical Preparations Industry

114th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Galecto (NASDAQ:GLTO) Frequently Asked Questions

Is Galecto a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Galecto stock.
View analyst ratings for Galecto
or view top-rated stocks.

What stocks does MarketBeat like better than Galecto?

Wall Street analysts have given Galecto a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Galecto wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Galecto?

Galecto saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 251,700 shares, a decline of 40.6% from the June 30th total of 423,600 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.7% of the shares of the company are sold short.
View Galecto's Short Interest

When is Galecto's next earnings date?

Galecto is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Galecto

How were Galecto's earnings last quarter?

Galecto, Inc. (NASDAQ:GLTO) issued its earnings results on Tuesday, May, 4th. The company reported ($0.53) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.07.
View Galecto's earnings history

What price target have analysts set for GLTO?

3 analysts have issued 1 year price targets for Galecto's stock. Their forecasts range from $12.00 to $16.00. On average, they expect Galecto's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 226.3% from the stock's current price.
View analysts' price targets for Galecto
or view top-rated stocks among Wall Street analysts.

Who are Galecto's key executives?

Galecto's management team includes the following people:
  • Dr. Hans T. Schambye, Co-Founder, Pres, CEO & Director (Age 55, Pay $644.98k)
  • Mr. Anders Pedersen, Chief Operating Officer (Age 61, Pay $449.66k)
  • Prof. Bertil Lindmark M.D., Ph.D., Chief Medical Officer (Age 66, Pay $602.63k)
  • Mr. Ulf J. Nilsson, Co-Founder
  • Dr. Hakon Leffler, Co-Founder
  • Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Co-Founder & Member of the Clinical Advisory Board - IPF
  • Mr. Jonathan P. Freve CPA, CPA, Chief Financial Officer (Age 43)
  • Mr. Garrett Winslow, Sr. VP & Gen. Counsel (Age 42)

Who are some of Galecto's key competitors?

When did Galecto IPO?

(GLTO) raised $86 million in an initial public offering on Thursday, October 29th 2020. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager.

What is Galecto's stock symbol?

Galecto trades on the NASDAQ under the ticker symbol "GLTO."

Who are Galecto's major shareholders?

Galecto's stock is owned by a number of retail and institutional investors. Top institutional investors include Asymmetry Capital Management L.P. (0.24%). Company insiders that own Galecto stock include Bertil Lindmark, Hans T Schambye and Jonathan Freve.
View institutional ownership trends for Galecto

Which major investors are selling Galecto stock?

GLTO stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P..
View insider buying and selling activity for Galecto
or view top insider-selling stocks.

How do I buy shares of Galecto?

Shares of GLTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galecto's stock price today?

One share of GLTO stock can currently be purchased for approximately $4.29.

How much money does Galecto make?

Galecto has a market capitalization of $108.37 million. The company earns $-34,840,000.00 in net income (profit) each year or ($7.62) on an earnings per share basis.

How many employees does Galecto have?

Galecto employs 28 workers across the globe.

What is Galecto's official website?

The official website for Galecto is

Where are Galecto's headquarters?

Galecto is headquartered at GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200.

How can I contact Galecto?

Galecto's mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The company can be reached via phone at 45 70 70 52 10.

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.